LungÕ 2026 – Virtual Global Congress on Lung Oncology
ASTRIDE Bridges the Gap: Serplulimab Matches 32% Two-Year Survival in U.S. Patients with Small Cell Lung Cancer
Daniel Malarek and a Wish for Oncology: A Future Where Breakthroughs Reach Every Patient
From TAILORx to OPTIMA: Genomic Testing Expands Chemotherapy De-escalation in Higher-Risk HR-Positive Breast Cancer
BeOne Medicines’ Zanubrutinib Combination Gains FDA Priority Review for First-Line Mantle Cell Lymphoma
London Global Cancer Week 2026: Highlights From November 2–4
Expert Discussion at COGC 2026: The Right First Investments in Precision Oncology
Perioperative Ivonescimab Shows Promising Pathological Responses in Resectable NSCLC: Phase II Trial Reports 70.1% MPR and 50.7% pCR
